Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel-Reference-Cited by-同舟云学术

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

Published:2022-11-06 Issue:1 Volume:4 Page:174-183
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Leleu Xavier¹^ORCID,Katodritou Eirini²^ORCID,Kuehr Thomas³,Terpos Evangelos⁴^ORCID,Caers Jo⁵^ORCID,Zambello Renato⁶^ORCID,Brescianini Alessandra⁷,Liang Tony⁸,Wetten Sally⁹,Badelita Sorina N.¹⁰^ORCID

Affiliation:

1. Department of Haematology University Hospital Centre La Miletrie and Inserm Poitiers France

2. Department of Haematology Theagenio Cancer Hospital Thessaloniki Greece

3. Department of Internal Medicine IV Academic Teaching Hospital Wels‐Grieskirchen Wels Austria

4. Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Athens Greece

5. Department of Haematology Liège University Hospital Centre Liège Belgium

6. Department of Medicine Haematology and Clinical Immunology Branch, University of Padua Padua Italy

7. Research and Development Department Amgen (Europe) GmbH Rotkreuz Switzerland

8. Department of Biostatistics Parexel International Taipei Taiwan

9. Center for Observational Research Amgen Ltd Uxbridge UK

10. Department of Hematology Fundeni Clinical Institute Bucharest Romania

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.595

Reference23 articles.

1. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

2. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

3. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

4. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

5. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland;eJHaem;2023-10-06

2. Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe;Cancers;2022-10-28